The long-acting rhG-CSF market is projected to grow from USD 4.5 billion in 2025 to USD 8.2 billion by 2035, at a CAGR of 6.2%. Long-acting rhG-CSF will dominate with a 58.7% market share, while neoplastic diseases will lead the application segment with a 76.4% share.